TABLE 2.
Hazard ratio | 95% CI | p | |
---|---|---|---|
(A) Overall survival | |||
Race | |||
EA | 1.00 | ||
AA | 1.34 | (0.71, 2.54) | 0.359 |
Age (years) | |||
<65 | 1.00 | ||
≥65 | 1.55 | (0.91, 2.66) | 0.110 |
Gender | |||
Female | 1.00 | ||
Male | 1.48 | (0.88, 2.47) | 0.138 |
Cancer stage | |||
Local (Stage 1) | 1.00 | ||
Advanced (Stage 2–4) | 2.29 | (0.83, 6.32) | 0.111 |
Hazard ratio | 95% CI | p | |
---|---|---|---|
(B) Progression‐free survival | |||
Race | |||
EA | 1.00 | ||
AA | 1.75 | (1.04, 2.95) | 0.035* |
Age (years) | |||
<65 | 1.00 | ||
≥65 | 0.69 | (0.43, 1.11) | 0.130 |
Gender | |||
Female | 1.00 | ||
Male | 1.82 | (1.12, 2.95) | 0.015** |
Cancer stage | |||
Local (Stage 1) | 1.00 | ||
Advanced (Stage 2–4) | 3.60 | (1.31, 9.88) | 0.013* |
p < 0.05;
p < 0.01;
p < 0.001.